Pfizer (PFE) Amortization - Intangibles (2009 - 2026)
Pfizer (PFE) posted quarterly Amortization - Intangibles of $1.2 billion for Q1 2026, down 2.31% year-over-year from $1.2 billion in Q1 2025, and down 7.14% quarter-over-quarter from $1.3 billion in Q4 2025.
Pfizer (PFE) Amortization - Intangibles (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Amortization - Intangibles for 18 consecutive years, with $1.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization - Intangibles fell 2.31% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $4.9 billion (down 36.91% YoY), while the FY2025 annual figure was $4.9 billion, down 7.79% from the prior year.
- Amortization - Intangibles eased to $1.2 billion in Q1 2026 per PFE's latest filing, from $1.3 billion in the prior quarter.
- Across five years, Amortization - Intangibles topped out at $3.9 billion in Q3 2024 and bottomed at $822.0 million in Q3 2022.
- Historically, Amortization - Intangibles has averaged $1.4 billion across 5 years, with a median of $1.2 billion in 2025.
- Annual changes were most pronounced in 2023 — Amortization - Intangibles jumped 44.04% — and 2025, when it tumbled 68.86%.
- Pfizer's Amortization - Intangibles stood at $822.0 million in 2022, then surged by 54.14% to $1.3 billion in 2023, then surged by 209.94% to $3.9 billion in 2024, then plunged by 67.56% to $1.3 billion in 2025, then retreated by 7.14% to $1.2 billion in 2026.
- Business Quant data shows PFE's Amortization - Intangibles at $1.2 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 1.19 Bn |
| Mar 29, 2026 | 1.18 Bn |
| Dec 31, 2025 | 1.27 Bn |
| Sep 28, 2025 | 1.22 Bn |
| Jun 29, 2025 | 1.21 Bn |
| Mar 30, 2025 | 1.21 Bn |
| Sep 29, 2024 | 3.93 Bn |
| Jun 30, 2024 | 1.31 Bn |
| Mar 31, 2024 | 1.31 Bn |
| Dec 31, 2023 | 1.27 Bn |
| Jul 2, 2023 | 1.18 Bn |
| Apr 2, 2023 | 1.10 Bn |
| Jul 3, 2022 | 822.00 Mn |
| Apr 3, 2022 | 835.00 Mn |
| Oct 3, 2021 | 2.74 Bn |
| Jul 4, 2021 | 917.00 Mn |
| Apr 4, 2021 | 858.00 Mn |
| Sep 27, 2020 | 2.58 Bn |
| Jun 28, 2020 | 869.00 Mn |
| Mar 29, 2020 | 849.00 Mn |